CompletedNCT01927965Updated Mar 6, 2017

Study of Minnelide™ in Patients With Advanced GI Tumors

A Phase 1 interventional study of Minnelide™ 001 in Advanced Gastrointestinal Tumors, sponsored by Minneamrita Therapeutics LLC. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-06.

Sponsored by Minneamrita Therapeutics LLC · Phase 1, Interventional, and Treatment

Phase: Phase 1
Study type: Interventional
Enrollment: 45
Allocation: Not applicable
Ages: 18 Years and older
Sex: All

Study summary

The primary objective of this study is to determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of Minnelide™ and to establish the dose of Minnelide™ recommended for future phase 2 protocol

Read the detailed description

This is a Phase 1, open label, multicenter, dose-escalation study of safety, pharmacokinetics, and pharmacodynamics of Minnelide™

Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days. Dose escalation will follow a modified Fibonacci design.

Conditions studied

Advanced Gastrointestinal Tumors

Browse trials for

Keywords

gastrointestinal tract
GI tract
advanced gastrointestinal tumors
gastrointestinal tumors
GI tumors
biliary
gallbladder,
colorectal,
gastric,
hepatocellular
esophageal
pancreatic

In context

Digestive System Neoplasms

311 studies on the registry are indexed under Digestive System Neoplasms; 83 are open to participants now.

This study's enrollment of 45 is close to the median of 50 across 233 interventional studies indexed under Digestive System Neoplasms.

Browse Digestive System Neoplasms studies →

Lead sponsor

Minneamrita Therapeutics LLC is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No

ELIGIBILITY CRITERIA:

Inclusion criteria

Inclusion Criteria:

Histologically or cytologically confirmed gastrointestinal (GI) carcinoma, which has progressed on standard therapies (surgery, radiotherapy, endocrine therapy, chemotherapy), for which effective therapy is not available or for which patients are not a candidate for or intolerant of such therapies.
Have one or more metastatic tumors measurable on CT scan or locally advanced measurable disease that has clearly progressed after prior treatment per RECIST criteria.
Male and female patients at least 18 years of age
Laboratory data as specified:
- Hematology: ANC >1500 cells/mm3, platelet count > 150,000 cells/mm3 and Hemoglobin > 9 g/dL
- Hepatic: Direct bilirubin ≤1.5 X ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5 X ULN. For patients with known liver metastases or liver neoplasms, then ALT or AST ≤ 5.0 X ULN is allowed
- Renal: serum creatinine WNL or calculated creatinine clearance ≥ 50 mL/min/1.73m2 for patients with creatinine levels above institutional normal
- Urinalysis: No clinically significant abnormalities
- Coagulation: INR within normal limits, PTT within normal limits
Estimated life expectancy of at least 3 months
Karnofsky Performance ≥ 70%
A negative serum pregnancy test (if female)
For men and women of child-producing potential - willingness to employ appropriate contraceptive methods (including abstinence) during the study.
Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments.

Exclusion criteria

Exclusion Criteria:

Women who are pregnant or nursing. NOTE: Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG.
Baseline QTc exceeding 450 msec (470 msec for females) using the Bazetts formula and/or patients receiving class 1A or class III antiarrythmic agents.
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
Treatment with radiotherapy, chemotherapy or investigational therapy within 1 month (or 5 half lifes for cytotoxics) prior to study entry (6 weeks for nitrosoureas or Mitomycin C).
Known HIV, Hepatitis A, B or Hepatitis C infection
Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor.
Participation in concurrent study of an investigational agent or device.
Unwillingness or inability to comply with procedures required in this protocol.
Any other condition including but not limited to major co-morbidities, which in the opinion of the investigator would render the patient ineligible.

Study design

Phase: Phase 1
Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrollment: 45 participants (actual)

Study arms

Experimental
Minnelide™ 001
A Phase 1, Multi-Center, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™ given daily for 21 days followed by 7 days off schedule in patients with Advanced GI Tumors
Drug: Minnelide™ 001

Interventions

DrugMinnelide™ 001
Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days.
Also known as: Minnelide

What researchers measure

Primary outcomes

To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of Minnelide™
The MTD will be determined using a 3 + 3 design and will continue until 2 patients at any dose level experience a DLT. A DLT will be defined as Grade 4 neutropenia lasting ≥ 5 days or Grade 3 or 4 neutropenia with fever and/or infection;Grade 4 thrombocytopenia (or Grade 3 with bleeding);Grade 3 or 4 treatment-related non-hematological toxicity (Grade 3 nausea, vomiting or diarrhea that last \> 72 hours despite maximal treatment constitutes a DLT, insufficient treatment will not constitute an exception to the DLT criteria, as this would constitute inadequate conduct of the study); Dosing delay greater than 2 weeks due to treatment-emergent AEs or related severe laboratory abnormalities.
Time frame: 24 months
To establish the dose of Minnelide™ recommended for future phase 2 protocol
Once the MTD has been determined this will be the dose going forward in phase 2 studies
Time frame: 24 months

Secondary outcomes

To determine the pharmacokinetics of Minnelide™
Plasma concentration data will be used to determine the following PK parameters: * AUC Area under the concentration curve * Cmax Maximum plasma concentration * Tmax Time to maximum plasma concentration * t1/2 Terminal phase half life * CL/F Total body clearance * Vd/F Apparent volume of distribution
Time frame: 24 months
To observe patients for any evidence of antitumor activity of Minnelide™ per RECIST criteria
Objective measurements of tumor size will be recorded from PET, CT scan and other measures.
Time frame: 24 months
To determine pharmacodynamic effect of Minnelide™ on HSP70 levels. And to explore pharmacodynamics effect of Minnelide™ on PET Scans and using Choi criteria on the CT scans.
As part of exploratory PD, the following assessments will be performed: * Biomarkers including CA19-9 (or CA125, CEA if non-secretors for pancreas cancer), CEA and CA125 as applicable, any tumor marker appropriate to the given cancer or that is known to be elevated in a given patient will be evaluated according the Investigator's discretion, prior to every Cycle. * Serum HSP70 levels * PET Scans * Evaluation of CT scans using Choi criteria
Time frame: 24 months

Study locations

2 sites

Virginia G. Piper Cancer Center at Scottsdale Healthcare
Scottsdale, Arizona 85258, United States
University of Minnesota Masonic Cancer Clinic
Minneapolis, Minnesota 55455, United States

References and documents

Publications

Antonoff MB, Chugh R, Borja-Cacho D, Dudeja V, Clawson KA, Skube SJ, Sorenson BS, Saltzman DA, Vickers SM, Saluja AK. Triptolide therapy for neuroblastoma decreases cell viability in vitro and inhibits tumor growth in vivo. Surgery. 2009 Aug;146(2):282-90. doi: 10.1016/j.surg.2009.04.023. PubMed 19628086 ↗
Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, Evans RL, Andreeff M. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood. 2006 Jul 15;108(2):630-7. doi: 10.1182/blood-2005-09-3898. Epub 2006 Mar 23. PubMed 16556893 ↗
Choi YJ, Kim TG, Kim YH, Lee SH, Kwon YK, Suh SI, Park JW, Kwon TK. Immunosuppressant PG490 (triptolide) induces apoptosis through the activation of caspase-3 and down-regulation of XIAP in U937 cells. Biochem Pharmacol. 2003 Jul 15;66(2):273-80. doi: 10.1016/s0006-2952(03)00282-x. PubMed 12826269 ↗
Liu Q, Chen T, Chen H, Zhang M, Li N, Lu Z, Ma P, Cao X. Triptolide (PG-490) induces apoptosis of dendritic cells through sequential p38 MAP kinase phosphorylation and caspase 3 activation. Biochem Biophys Res Commun. 2004 Jul 2;319(3):980-6. doi: 10.1016/j.bbrc.2004.04.201. PubMed 15184078 ↗
Phillips PA, Dudeja V, McCarroll JA, Borja-Cacho D, Dawra RK, Grizzle WE, Vickers SM, Saluja AK. Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res. 2007 Oct 1;67(19):9407-16. doi: 10.1158/0008-5472.CAN-07-1077. PubMed 17909050 ↗
Shamon LA, Pezzuto JM, Graves JM, Mehta RR, Wangcharoentrakul S, Sangsuwan R, Chaichana S, Tuchinda P, Cleason P, Reutrakul V. Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from Tripterygium wilfordii. Cancer Lett. 1997 Jan 15;112(1):113-7. doi: 10.1016/S0304-3835(96)04554-5. PubMed 9029176 ↗
Tengchaisri T, Chawengkirttikul R, Rachaphaew N, Reutrakul V, Sangsuwan R, Sirisinha S. Antitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamsters. Cancer Lett. 1998 Nov 27;133(2):169-75. doi: 10.1016/s0304-3835(98)00222-5. PubMed 10072166 ↗
Wang X, Matta R, Shen G, Nelin LD, Pei D, Liu Y. Mechanism of triptolide-induced apoptosis: Effect on caspase activation and Bid cleavage and essentiality of the hydroxyl group of triptolide. J Mol Med (Berl). 2006 May;84(5):405-15. doi: 10.1007/s00109-005-0022-4. Epub 2005 Dec 30. PubMed 16385419 ↗
Yang S, Chen J, Guo Z, Xu XM, Wang L, Pei XF, Yang J, Underhill CB, Zhang L. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther. 2003 Jan;2(1):65-72. PubMed 12533674 ↗

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Mar 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT01927965
Lead sponsor: Minneamrita Therapeutics LLC
Responsible party: Sponsor
First posted: Aug 23, 2013
Start date: Aug 2013
Primary completion: Oct 2016
Completion: Dec 2016
Last update: Mar 6, 2017

Study contacts

Mohana Velagapudi, MD

study director · Minneamrita Therapeutics LLC

Linda Vocila, BSN

study director · Translational Drug Development

Oversight

Data monitoring committee: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Digestive System Neoplasms→

Other studies from this sponsor

Minneamrita Therapeutics LLC

Start the discussion